Market Overview

Medtronic Says Sentrino CGM System Wins CE Mark Approval

Share:
Related MDT
Medtronic Adds New Resolute Onyx Drug-Eluting Stent Sizes, and Expands Indications
Are Share Repurchases On The Horizon?
MedTech Series: Why Medical Technology Companies Should Have A Place In Your Portfolio (Seeking Alpha)

Medtronic, Inc. (NYSE: MDT) today announced CE (Conformité Européenne) Mark approval of its innovative Sentrino® Continuous Glucose Management System, the first minimally invasive continuous glucose monitoring (CGM) system specifically designed for use in hospital critical care units (CCU). The Sentrino CGM System provides real-time trend data that serves as an early warning system, allowing clinicians to appropriately intervene to prevent glycemic excursions and maximize the patient's time in the target range.  In addition, the system integrates simply into the clinical workflow in the hospital to improve the quality and efficiency of maintaining glucose control.

Improved glucose management in critical care patients may reduce morbidity, mortality and the length of stay.^1-3 While glucose control is a standard practice for diabetic and non-diabetic patients in the CCU, it's difficult to achieve.  The Sentrino CGM System and the trending data it provides help optimize glucose management practices. Sentrino is an investigational device only in the US and not approved for sale in the US.

Posted-In: News

 

Related Articles (MDT)

View Comments and Join the Discussion!

Get Benzinga's Newsletters